This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by GELLER, J. Articles by LOZA, D. Search for Related Content PubMed PubMed Citation Articles by GELLER, J. Articles by LOZA, D.

Medical Castration of Males with Megestrol Acetate and Small Doses of Diethylstilbestrol^*

Mercy Hospital and Medical Center, San Diego California 92103

Address requests for reprints to: Jack Geller, M.D., Mercy Hospital and Medical Center, 4077 Fifth Avenue, San Diego, California 92103.

An alternative program for medical castration for treatment of prostate cancer has been developed using a progestational antiandrogen, megestrol acetate (MA), in combination with small doses of diethylstilbestrol (DES; 0.1 mg/day). The administration of MA (40–80 mg/day) with 0.1 mg DES to nine patients resulted in castrate levels of plasma testosterone (<0.4 ng/ml) and significant suppression of both FSH and LH (P < 0.05) for up to 12 months. Although large clinical trials must ultimately establish its safety, clinical side effects of this combined therapy to date have consisted of mild gynecomastia in two patients. The symptoms did not necessitatediscontinuing the medications. It is concluded that the use of 0.1 mg DES with a minimum of 40 mg/day MA results in medical castration with sustained suppression of plasmatestosterone. Because of the possible additional therapeutic advantage of blockade of intracellular androgen-mediated action by MA in androgen-dependent tumors, this combined therapy should be further explored as a possible initial treatment of choice for advanced prostate cancer.

^* This work was supported by the National Cancer Institute (NIH Grant 2-R26-CA-18003-04).

Received June 12, 1980.

This article has been cited by other articles:

				C. P. Lambert, D. H. Sullivan, S. A. Freeling, D. M. Lindquist, and W. J. Evans Effects of Testosterone Replacement and/or Resistance Exercise on the Composition of Megestrol Acetate Stimulated Weight Gain in Elderly Men: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2100 - 2106. [Abstract] [Full Text] [PDF]

				M. A. Eisenberger, B. A. Blumenstein, E. D. Crawford, G. Miller, D. G. McLeod, P. J. Loehrer, G. Wilding, K. Sears, D. J. Culkin, I. M. Thompson, et al. Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer N. Engl. J. Med., October 8, 1998; 339(15): 1036 - 1042. [Abstract] [Full Text] [PDF]

				C. B. Hammond and S. J. Ory Diagnostic and Therapeutic Uses of Gonadotropin-Releasing Hormone Arch Intern Med, September 1, 1985; 145(9): 1690 - 1697. [Abstract] [PDF]